Title

Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.

Authors

Alexa Cohen
Tanya M Spektor
Laura Stampleman
Alberto Bessudo
Peter J Rosen, Providence Saint Joseph Medical Center, Burbank, CA, USA
Leonard M Klein
Thomas Woliver
Marshall Flam
Shahrooz Eshaghian
Youram Nassir
Tina Maluso
Regina A Swift
Robert Vescio
James R Berenson

Document Type

Article

Publication Date

1-1-2018

Publication Title

British journal of haematology

Keywords

Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome

Abstract

Immunomodulatory drugs including thalidomide, lenalidomide (LEN) and pomalidomide (POM), are effective for treating multiple myeloma (MM). POM has shown enhanced efficacy with dexamethasone (DEX). Pegylated liposomal doxorubicin (PLD) with bortezomib is US Food and Drug Administration-approved for treating MM. PLD with LEN or thalidomide has shown efficacy for MM patients. LEN with DEX, PLD and bortezomib achieves high response rates. We evaluated the combination of POM with DEX 40 mg and PLD 5 mg/m

Clinical Institute

Cancer

Department

Oncology

Department

Pharmacy

Recommended Citation

Cohen, Alexa; Spektor, Tanya M; Stampleman, Laura; Bessudo, Alberto; Rosen, Peter J; Klein, Leonard M; Woliver, Thomas; Flam, Marshall; Eshaghian, Shahrooz; Nassir, Youram; Maluso, Tina; Swift, Regina A; Vescio, Robert; and Berenson, James R, "Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma." (2018). Articles, Abstracts, and Reports. 84.
https://digitalcommons.providence.org/publications/84